Analysis of Monitoring Results on Cyclosporin A Plasma Concentration in Bone Marrow Transplantation Recipients
- VernacularTitle:骨髓移植受者环孢素A血药浓度监测结果分析
- Author:
Yuqin YIN
;
Guili XU
- Publication Type:Journal Article
- Keywords:
Bone marrow transplantation;
Cyclosporin A;
Fluorescence polarization immunoassay(FPIA);
Therapeutic drug monitoring(TDM)
- From:
China Pharmacy
2001;0(11):-
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the efficacy and safety of the effective blood concentration of cyclosporin A in patients after bone marrow transplantation.METHODS:By fluorescence polarization immunoassay(FPIA),the whole blood trough concentration of CsA in 14 patients after undergoing bone marrow transplantation was monitored for 216 times in total from day 1 to day 466,and the monitoring results were analyzed.RESULTS:The effective blood concentrations of CsA in patients with chronic myelocytic leukemia(CML),acute non lymphocytic leukemia(AML),acute lymphoblastic leukemia (ALL),Mediterranean disease(THAL),and pancytopenia were(50～450) ng?mL~(-1),(100～450) ng?mL~(-1),(100～350) ng?mL~(-1)(200～500) ng?mL~(-1),and(250～500) ng?mL~(-1),respectively.Rejection reaction appeared in 7 cases after bone marrow transplantation,with whole blood trough concentration of CsA ranged from 67.4 ng?mL~(-1) to 189.34 ng?mL_(-1) (125.44?39.56 ng?mL~(-1)on average).Adverse drug reaction appeared in 3 cases,with trough concentration of CsA ranged from 412.5 ng?mL~(-1) to 548.62 ng?mL~(-1)(481.39?68.08 ng?mL~(-1) on average).CONCLUSION:Timely monitoring of plasma concentration of CsA and modifying of the dosage regimen can avoid the occurrence of rejection reaction and adverse drug reaction,which is of great significance for patients' medication safety and efficacy.
